PMC:7212949 / 42147-43972 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T240","span":{"begin":900,"end":906},"obj":"Body_part"},{"id":"T241","span":{"begin":942,"end":948},"obj":"Body_part"},{"id":"T242","span":{"begin":957,"end":960},"obj":"Body_part"},{"id":"T243","span":{"begin":970,"end":975},"obj":"Body_part"},{"id":"T244","span":{"begin":1032,"end":1040},"obj":"Body_part"},{"id":"T245","span":{"begin":1049,"end":1052},"obj":"Body_part"},{"id":"T246","span":{"begin":1062,"end":1067},"obj":"Body_part"},{"id":"T247","span":{"begin":1265,"end":1270},"obj":"Body_part"},{"id":"T248","span":{"begin":1271,"end":1274},"obj":"Body_part"},{"id":"T249","span":{"begin":1662,"end":1667},"obj":"Body_part"}],"attributes":[{"id":"A240","pred":"fma_id","subj":"T240","obj":"http://purl.org/sig/ont/fma/fma59862"},{"id":"A241","pred":"fma_id","subj":"T241","obj":"http://purl.org/sig/ont/fma/fma59862"},{"id":"A242","pred":"fma_id","subj":"T242","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A243","pred":"fma_id","subj":"T243","obj":"http://purl.org/sig/ont/fma/fma64183"},{"id":"A244","pred":"fma_id","subj":"T244","obj":"http://purl.org/sig/ont/fma/fma62864"},{"id":"A245","pred":"fma_id","subj":"T245","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A246","pred":"fma_id","subj":"T246","obj":"http://purl.org/sig/ont/fma/fma64183"},{"id":"A247","pred":"fma_id","subj":"T247","obj":"http://purl.org/sig/ont/fma/fma64183"},{"id":"A248","pred":"fma_id","subj":"T248","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A249","pred":"fma_id","subj":"T249","obj":"http://purl.org/sig/ont/fma/fma64183"}],"text":"COVID-19\nStudy Wang et al (2020)N = 138, confirmed casesClinicopathologic study Guan et al (2020)N = 1099, confirmed casesRetrospective study To et al (2020)N = 12, suspected casesClinicopathologic study Xie et al (2020)N = 19 suspected (9 confirmed cases)Clinicopathologic study Pan et al (2020)N = 204, confirmed casesRetrospective study Wu et al (2020)N = 74, confirmed casesClinicopathologic study\nClinical features • Anorexia (39.9)\n• Diarrhea (10.1)\n• Nausea (10.1%)\n• Vomiting (3.6%)\n• Abdominal pain (2.2%) • Diarrhea (3.8%)\n• Nausea or vomiting (5%) Diarrhea (11.1% of confirmed) • Any GI symptom: 50.5%\n• Only GI symptoms: 0.03%\n• Loss of appetite (39.7% of total, 78.6% of all GI symptoms)\n• Diarrhea (17.1%, 34%, usually 3/day)\n• Vomiting (0.02%, 3.9%)\n• Abdominal pain (0.01%, 1.9%) Diarrhea/Vomit/Stomachache (44.6%)\nKey findings on investigations N/A N/A • 2019-nCoV detected in 91.7% saliva samples\n• Virus cultured from 3/12 saliva samples RNA positive stool samples: 88.9% of confirmed (overall 42%) ↑ALT, AST↑ PT↓monocyte count • RNA positive stool samples: 55%\nKey study findings and message ICU patients more likely to have anorexia and abdominal pain (P \u003c 0.001, P = 0.02) GI symptoms less common • Presence of GI symptoms not associated with stool RNA positivity\n• Fecal transmission possible • Patients with GI symptoms had longer interval from symptom onset to admission (P = 0.013)\n• GI symptoms worsened with severity of disease\n• Patients with GI symptoms more likely to get antibiotics (P = 0.018)\n• No association presence of GI symptoms with total hospital stay, ICU days or mortality • Presence of GI symptoms not associated with stool positivity\n• Prolonged fecal viral shedding up to 5 weeks\n• Disease severity not associated with prolonged fecal viral shedding\n• Fecal transmission possible"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T136","span":{"begin":805,"end":810},"obj":"Body_part"},{"id":"T137","span":{"begin":900,"end":906},"obj":"Body_part"},{"id":"T138","span":{"begin":942,"end":948},"obj":"Body_part"},{"id":"T139","span":{"begin":970,"end":975},"obj":"Body_part"},{"id":"T140","span":{"begin":1062,"end":1067},"obj":"Body_part"},{"id":"T141","span":{"begin":1265,"end":1270},"obj":"Body_part"},{"id":"T142","span":{"begin":1662,"end":1667},"obj":"Body_part"}],"attributes":[{"id":"A136","pred":"uberon_id","subj":"T136","obj":"http://purl.obolibrary.org/obo/UBERON_0000172"},{"id":"A137","pred":"uberon_id","subj":"T137","obj":"http://purl.obolibrary.org/obo/UBERON_0001836"},{"id":"A138","pred":"uberon_id","subj":"T138","obj":"http://purl.obolibrary.org/obo/UBERON_0001836"},{"id":"A139","pred":"uberon_id","subj":"T139","obj":"http://purl.obolibrary.org/obo/UBERON_0001988"},{"id":"A140","pred":"uberon_id","subj":"T140","obj":"http://purl.obolibrary.org/obo/UBERON_0001988"},{"id":"A141","pred":"uberon_id","subj":"T141","obj":"http://purl.obolibrary.org/obo/UBERON_0001988"},{"id":"A142","pred":"uberon_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/UBERON_0001988"}],"text":"COVID-19\nStudy Wang et al (2020)N = 138, confirmed casesClinicopathologic study Guan et al (2020)N = 1099, confirmed casesRetrospective study To et al (2020)N = 12, suspected casesClinicopathologic study Xie et al (2020)N = 19 suspected (9 confirmed cases)Clinicopathologic study Pan et al (2020)N = 204, confirmed casesRetrospective study Wu et al (2020)N = 74, confirmed casesClinicopathologic study\nClinical features • Anorexia (39.9)\n• Diarrhea (10.1)\n• Nausea (10.1%)\n• Vomiting (3.6%)\n• Abdominal pain (2.2%) • Diarrhea (3.8%)\n• Nausea or vomiting (5%) Diarrhea (11.1% of confirmed) • Any GI symptom: 50.5%\n• Only GI symptoms: 0.03%\n• Loss of appetite (39.7% of total, 78.6% of all GI symptoms)\n• Diarrhea (17.1%, 34%, usually 3/day)\n• Vomiting (0.02%, 3.9%)\n• Abdominal pain (0.01%, 1.9%) Diarrhea/Vomit/Stomachache (44.6%)\nKey findings on investigations N/A N/A • 2019-nCoV detected in 91.7% saliva samples\n• Virus cultured from 3/12 saliva samples RNA positive stool samples: 88.9% of confirmed (overall 42%) ↑ALT, AST↑ PT↓monocyte count • RNA positive stool samples: 55%\nKey study findings and message ICU patients more likely to have anorexia and abdominal pain (P \u003c 0.001, P = 0.02) GI symptoms less common • Presence of GI symptoms not associated with stool RNA positivity\n• Fecal transmission possible • Patients with GI symptoms had longer interval from symptom onset to admission (P = 0.013)\n• GI symptoms worsened with severity of disease\n• Patients with GI symptoms more likely to get antibiotics (P = 0.018)\n• No association presence of GI symptoms with total hospital stay, ICU days or mortality • Presence of GI symptoms not associated with stool positivity\n• Prolonged fecal viral shedding up to 5 weeks\n• Disease severity not associated with prolonged fecal viral shedding\n• Fecal transmission possible"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T296","span":{"begin":0,"end":8},"obj":"Disease"},{"id":"T297","span":{"begin":440,"end":448},"obj":"Disease"},{"id":"T298","span":{"begin":517,"end":525},"obj":"Disease"},{"id":"T299","span":{"begin":559,"end":567},"obj":"Disease"},{"id":"T300","span":{"begin":703,"end":711},"obj":"Disease"},{"id":"T301","span":{"begin":796,"end":804},"obj":"Disease"}],"attributes":[{"id":"A296","pred":"mondo_id","subj":"T296","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A297","pred":"mondo_id","subj":"T297","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"},{"id":"A298","pred":"mondo_id","subj":"T298","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"},{"id":"A299","pred":"mondo_id","subj":"T299","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"},{"id":"A300","pred":"mondo_id","subj":"T300","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"},{"id":"A301","pred":"mondo_id","subj":"T301","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"}],"text":"COVID-19\nStudy Wang et al (2020)N = 138, confirmed casesClinicopathologic study Guan et al (2020)N = 1099, confirmed casesRetrospective study To et al (2020)N = 12, suspected casesClinicopathologic study Xie et al (2020)N = 19 suspected (9 confirmed cases)Clinicopathologic study Pan et al (2020)N = 204, confirmed casesRetrospective study Wu et al (2020)N = 74, confirmed casesClinicopathologic study\nClinical features • Anorexia (39.9)\n• Diarrhea (10.1)\n• Nausea (10.1%)\n• Vomiting (3.6%)\n• Abdominal pain (2.2%) • Diarrhea (3.8%)\n• Nausea or vomiting (5%) Diarrhea (11.1% of confirmed) • Any GI symptom: 50.5%\n• Only GI symptoms: 0.03%\n• Loss of appetite (39.7% of total, 78.6% of all GI symptoms)\n• Diarrhea (17.1%, 34%, usually 3/day)\n• Vomiting (0.02%, 3.9%)\n• Abdominal pain (0.01%, 1.9%) Diarrhea/Vomit/Stomachache (44.6%)\nKey findings on investigations N/A N/A • 2019-nCoV detected in 91.7% saliva samples\n• Virus cultured from 3/12 saliva samples RNA positive stool samples: 88.9% of confirmed (overall 42%) ↑ALT, AST↑ PT↓monocyte count • RNA positive stool samples: 55%\nKey study findings and message ICU patients more likely to have anorexia and abdominal pain (P \u003c 0.001, P = 0.02) GI symptoms less common • Presence of GI symptoms not associated with stool RNA positivity\n• Fecal transmission possible • Patients with GI symptoms had longer interval from symptom onset to admission (P = 0.013)\n• GI symptoms worsened with severity of disease\n• Patients with GI symptoms more likely to get antibiotics (P = 0.018)\n• No association presence of GI symptoms with total hospital stay, ICU days or mortality • Presence of GI symptoms not associated with stool positivity\n• Prolonged fecal viral shedding up to 5 weeks\n• Disease severity not associated with prolonged fecal viral shedding\n• Fecal transmission possible"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T430","span":{"begin":280,"end":283},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9596"},{"id":"T431","span":{"begin":720,"end":722},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T432","span":{"begin":864,"end":865},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T433","span":{"begin":868,"end":869},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T434","span":{"begin":917,"end":922},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T435","span":{"begin":1032,"end":1040},"obj":"http://purl.obolibrary.org/obo/CL_0000576"}],"text":"COVID-19\nStudy Wang et al (2020)N = 138, confirmed casesClinicopathologic study Guan et al (2020)N = 1099, confirmed casesRetrospective study To et al (2020)N = 12, suspected casesClinicopathologic study Xie et al (2020)N = 19 suspected (9 confirmed cases)Clinicopathologic study Pan et al (2020)N = 204, confirmed casesRetrospective study Wu et al (2020)N = 74, confirmed casesClinicopathologic study\nClinical features • Anorexia (39.9)\n• Diarrhea (10.1)\n• Nausea (10.1%)\n• Vomiting (3.6%)\n• Abdominal pain (2.2%) • Diarrhea (3.8%)\n• Nausea or vomiting (5%) Diarrhea (11.1% of confirmed) • Any GI symptom: 50.5%\n• Only GI symptoms: 0.03%\n• Loss of appetite (39.7% of total, 78.6% of all GI symptoms)\n• Diarrhea (17.1%, 34%, usually 3/day)\n• Vomiting (0.02%, 3.9%)\n• Abdominal pain (0.01%, 1.9%) Diarrhea/Vomit/Stomachache (44.6%)\nKey findings on investigations N/A N/A • 2019-nCoV detected in 91.7% saliva samples\n• Virus cultured from 3/12 saliva samples RNA positive stool samples: 88.9% of confirmed (overall 42%) ↑ALT, AST↑ PT↓monocyte count • RNA positive stool samples: 55%\nKey study findings and message ICU patients more likely to have anorexia and abdominal pain (P \u003c 0.001, P = 0.02) GI symptoms less common • Presence of GI symptoms not associated with stool RNA positivity\n• Fecal transmission possible • Patients with GI symptoms had longer interval from symptom onset to admission (P = 0.013)\n• GI symptoms worsened with severity of disease\n• Patients with GI symptoms more likely to get antibiotics (P = 0.018)\n• No association presence of GI symptoms with total hospital stay, ICU days or mortality • Presence of GI symptoms not associated with stool positivity\n• Prolonged fecal viral shedding up to 5 weeks\n• Disease severity not associated with prolonged fecal viral shedding\n• Fecal transmission possible"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T146","span":{"begin":595,"end":597},"obj":"Chemical"},{"id":"T147","span":{"begin":620,"end":622},"obj":"Chemical"},{"id":"T148","span":{"begin":688,"end":690},"obj":"Chemical"},{"id":"T149","span":{"begin":1024,"end":1027},"obj":"Chemical"},{"id":"T150","span":{"begin":1029,"end":1031},"obj":"Chemical"},{"id":"T151","span":{"begin":1195,"end":1197},"obj":"Chemical"},{"id":"T152","span":{"begin":1233,"end":1235},"obj":"Chemical"},{"id":"T153","span":{"begin":1332,"end":1334},"obj":"Chemical"},{"id":"T154","span":{"begin":1410,"end":1412},"obj":"Chemical"},{"id":"T155","span":{"begin":1472,"end":1474},"obj":"Chemical"},{"id":"T156","span":{"begin":1503,"end":1514},"obj":"Chemical"},{"id":"T157","span":{"begin":1556,"end":1558},"obj":"Chemical"},{"id":"T158","span":{"begin":1630,"end":1632},"obj":"Chemical"}],"attributes":[{"id":"A146","pred":"chebi_id","subj":"T146","obj":"http://purl.obolibrary.org/obo/CHEBI_73907"},{"id":"A147","pred":"chebi_id","subj":"T147","obj":"http://purl.obolibrary.org/obo/CHEBI_73907"},{"id":"A148","pred":"chebi_id","subj":"T148","obj":"http://purl.obolibrary.org/obo/CHEBI_73907"},{"id":"A149","pred":"chebi_id","subj":"T149","obj":"http://purl.obolibrary.org/obo/CHEBI_76649"},{"id":"A150","pred":"chebi_id","subj":"T150","obj":"http://purl.obolibrary.org/obo/CHEBI_141395"},{"id":"A151","pred":"chebi_id","subj":"T151","obj":"http://purl.obolibrary.org/obo/CHEBI_73907"},{"id":"A152","pred":"chebi_id","subj":"T152","obj":"http://purl.obolibrary.org/obo/CHEBI_73907"},{"id":"A153","pred":"chebi_id","subj":"T153","obj":"http://purl.obolibrary.org/obo/CHEBI_73907"},{"id":"A154","pred":"chebi_id","subj":"T154","obj":"http://purl.obolibrary.org/obo/CHEBI_73907"},{"id":"A155","pred":"chebi_id","subj":"T155","obj":"http://purl.obolibrary.org/obo/CHEBI_73907"},{"id":"A156","pred":"chebi_id","subj":"T156","obj":"http://purl.obolibrary.org/obo/CHEBI_33281"},{"id":"A157","pred":"chebi_id","subj":"T157","obj":"http://purl.obolibrary.org/obo/CHEBI_73907"},{"id":"A158","pred":"chebi_id","subj":"T158","obj":"http://purl.obolibrary.org/obo/CHEBI_73907"}],"text":"COVID-19\nStudy Wang et al (2020)N = 138, confirmed casesClinicopathologic study Guan et al (2020)N = 1099, confirmed casesRetrospective study To et al (2020)N = 12, suspected casesClinicopathologic study Xie et al (2020)N = 19 suspected (9 confirmed cases)Clinicopathologic study Pan et al (2020)N = 204, confirmed casesRetrospective study Wu et al (2020)N = 74, confirmed casesClinicopathologic study\nClinical features • Anorexia (39.9)\n• Diarrhea (10.1)\n• Nausea (10.1%)\n• Vomiting (3.6%)\n• Abdominal pain (2.2%) • Diarrhea (3.8%)\n• Nausea or vomiting (5%) Diarrhea (11.1% of confirmed) • Any GI symptom: 50.5%\n• Only GI symptoms: 0.03%\n• Loss of appetite (39.7% of total, 78.6% of all GI symptoms)\n• Diarrhea (17.1%, 34%, usually 3/day)\n• Vomiting (0.02%, 3.9%)\n• Abdominal pain (0.01%, 1.9%) Diarrhea/Vomit/Stomachache (44.6%)\nKey findings on investigations N/A N/A • 2019-nCoV detected in 91.7% saliva samples\n• Virus cultured from 3/12 saliva samples RNA positive stool samples: 88.9% of confirmed (overall 42%) ↑ALT, AST↑ PT↓monocyte count • RNA positive stool samples: 55%\nKey study findings and message ICU patients more likely to have anorexia and abdominal pain (P \u003c 0.001, P = 0.02) GI symptoms less common • Presence of GI symptoms not associated with stool RNA positivity\n• Fecal transmission possible • Patients with GI symptoms had longer interval from symptom onset to admission (P = 0.013)\n• GI symptoms worsened with severity of disease\n• Patients with GI symptoms more likely to get antibiotics (P = 0.018)\n• No association presence of GI symptoms with total hospital stay, ICU days or mortality • Presence of GI symptoms not associated with stool positivity\n• Prolonged fecal viral shedding up to 5 weeks\n• Disease severity not associated with prolonged fecal viral shedding\n• Fecal transmission possible"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T48","span":{"begin":1697,"end":1711},"obj":"http://purl.obolibrary.org/obo/GO_0019076"},{"id":"T49","span":{"begin":1781,"end":1795},"obj":"http://purl.obolibrary.org/obo/GO_0019076"}],"text":"COVID-19\nStudy Wang et al (2020)N = 138, confirmed casesClinicopathologic study Guan et al (2020)N = 1099, confirmed casesRetrospective study To et al (2020)N = 12, suspected casesClinicopathologic study Xie et al (2020)N = 19 suspected (9 confirmed cases)Clinicopathologic study Pan et al (2020)N = 204, confirmed casesRetrospective study Wu et al (2020)N = 74, confirmed casesClinicopathologic study\nClinical features • Anorexia (39.9)\n• Diarrhea (10.1)\n• Nausea (10.1%)\n• Vomiting (3.6%)\n• Abdominal pain (2.2%) • Diarrhea (3.8%)\n• Nausea or vomiting (5%) Diarrhea (11.1% of confirmed) • Any GI symptom: 50.5%\n• Only GI symptoms: 0.03%\n• Loss of appetite (39.7% of total, 78.6% of all GI symptoms)\n• Diarrhea (17.1%, 34%, usually 3/day)\n• Vomiting (0.02%, 3.9%)\n• Abdominal pain (0.01%, 1.9%) Diarrhea/Vomit/Stomachache (44.6%)\nKey findings on investigations N/A N/A • 2019-nCoV detected in 91.7% saliva samples\n• Virus cultured from 3/12 saliva samples RNA positive stool samples: 88.9% of confirmed (overall 42%) ↑ALT, AST↑ PT↓monocyte count • RNA positive stool samples: 55%\nKey study findings and message ICU patients more likely to have anorexia and abdominal pain (P \u003c 0.001, P = 0.02) GI symptoms less common • Presence of GI symptoms not associated with stool RNA positivity\n• Fecal transmission possible • Patients with GI symptoms had longer interval from symptom onset to admission (P = 0.013)\n• GI symptoms worsened with severity of disease\n• Patients with GI symptoms more likely to get antibiotics (P = 0.018)\n• No association presence of GI symptoms with total hospital stay, ICU days or mortality • Presence of GI symptoms not associated with stool positivity\n• Prolonged fecal viral shedding up to 5 weeks\n• Disease severity not associated with prolonged fecal viral shedding\n• Fecal transmission possible"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T241","span":{"begin":422,"end":430},"obj":"Phenotype"},{"id":"T242","span":{"begin":440,"end":448},"obj":"Phenotype"},{"id":"T243","span":{"begin":458,"end":464},"obj":"Phenotype"},{"id":"T244","span":{"begin":475,"end":483},"obj":"Phenotype"},{"id":"T245","span":{"begin":493,"end":507},"obj":"Phenotype"},{"id":"T246","span":{"begin":517,"end":525},"obj":"Phenotype"},{"id":"T247","span":{"begin":535,"end":553},"obj":"Phenotype"},{"id":"T248","span":{"begin":559,"end":567},"obj":"Phenotype"},{"id":"T249","span":{"begin":703,"end":711},"obj":"Phenotype"},{"id":"T250","span":{"begin":742,"end":750},"obj":"Phenotype"},{"id":"T251","span":{"begin":767,"end":781},"obj":"Phenotype"},{"id":"T252","span":{"begin":796,"end":804},"obj":"Phenotype"},{"id":"T253","span":{"begin":1145,"end":1153},"obj":"Phenotype"},{"id":"T254","span":{"begin":1158,"end":1172},"obj":"Phenotype"}],"attributes":[{"id":"A241","pred":"hp_id","subj":"T241","obj":"http://purl.obolibrary.org/obo/HP_0002039"},{"id":"A242","pred":"hp_id","subj":"T242","obj":"http://purl.obolibrary.org/obo/HP_0002014"},{"id":"A243","pred":"hp_id","subj":"T243","obj":"http://purl.obolibrary.org/obo/HP_0002018"},{"id":"A244","pred":"hp_id","subj":"T244","obj":"http://purl.obolibrary.org/obo/HP_0002013"},{"id":"A245","pred":"hp_id","subj":"T245","obj":"http://purl.obolibrary.org/obo/HP_0002027"},{"id":"A246","pred":"hp_id","subj":"T246","obj":"http://purl.obolibrary.org/obo/HP_0002014"},{"id":"A247","pred":"hp_id","subj":"T247","obj":"http://purl.obolibrary.org/obo/HP_0002017"},{"id":"A248","pred":"hp_id","subj":"T248","obj":"http://purl.obolibrary.org/obo/HP_0002014"},{"id":"A249","pred":"hp_id","subj":"T249","obj":"http://purl.obolibrary.org/obo/HP_0002014"},{"id":"A250","pred":"hp_id","subj":"T250","obj":"http://purl.obolibrary.org/obo/HP_0002013"},{"id":"A251","pred":"hp_id","subj":"T251","obj":"http://purl.obolibrary.org/obo/HP_0002027"},{"id":"A252","pred":"hp_id","subj":"T252","obj":"http://purl.obolibrary.org/obo/HP_0002014"},{"id":"A253","pred":"hp_id","subj":"T253","obj":"http://purl.obolibrary.org/obo/HP_0002039"},{"id":"A254","pred":"hp_id","subj":"T254","obj":"http://purl.obolibrary.org/obo/HP_0002027"}],"text":"COVID-19\nStudy Wang et al (2020)N = 138, confirmed casesClinicopathologic study Guan et al (2020)N = 1099, confirmed casesRetrospective study To et al (2020)N = 12, suspected casesClinicopathologic study Xie et al (2020)N = 19 suspected (9 confirmed cases)Clinicopathologic study Pan et al (2020)N = 204, confirmed casesRetrospective study Wu et al (2020)N = 74, confirmed casesClinicopathologic study\nClinical features • Anorexia (39.9)\n• Diarrhea (10.1)\n• Nausea (10.1%)\n• Vomiting (3.6%)\n• Abdominal pain (2.2%) • Diarrhea (3.8%)\n• Nausea or vomiting (5%) Diarrhea (11.1% of confirmed) • Any GI symptom: 50.5%\n• Only GI symptoms: 0.03%\n• Loss of appetite (39.7% of total, 78.6% of all GI symptoms)\n• Diarrhea (17.1%, 34%, usually 3/day)\n• Vomiting (0.02%, 3.9%)\n• Abdominal pain (0.01%, 1.9%) Diarrhea/Vomit/Stomachache (44.6%)\nKey findings on investigations N/A N/A • 2019-nCoV detected in 91.7% saliva samples\n• Virus cultured from 3/12 saliva samples RNA positive stool samples: 88.9% of confirmed (overall 42%) ↑ALT, AST↑ PT↓monocyte count • RNA positive stool samples: 55%\nKey study findings and message ICU patients more likely to have anorexia and abdominal pain (P \u003c 0.001, P = 0.02) GI symptoms less common • Presence of GI symptoms not associated with stool RNA positivity\n• Fecal transmission possible • Patients with GI symptoms had longer interval from symptom onset to admission (P = 0.013)\n• GI symptoms worsened with severity of disease\n• Patients with GI symptoms more likely to get antibiotics (P = 0.018)\n• No association presence of GI symptoms with total hospital stay, ICU days or mortality • Presence of GI symptoms not associated with stool positivity\n• Prolonged fecal viral shedding up to 5 weeks\n• Disease severity not associated with prolonged fecal viral shedding\n• Fecal transmission possible"}

{"project":"LitCovid-sentences","denotations":[{"id":"T438","span":{"begin":0,"end":8},"obj":"Sentence"},{"id":"T439","span":{"begin":9,"end":401},"obj":"Sentence"},{"id":"T440","span":{"begin":402,"end":437},"obj":"Sentence"},{"id":"T441","span":{"begin":438,"end":455},"obj":"Sentence"},{"id":"T442","span":{"begin":456,"end":472},"obj":"Sentence"},{"id":"T443","span":{"begin":473,"end":490},"obj":"Sentence"},{"id":"T444","span":{"begin":491,"end":532},"obj":"Sentence"},{"id":"T445","span":{"begin":533,"end":606},"obj":"Sentence"},{"id":"T446","span":{"begin":607,"end":612},"obj":"Sentence"},{"id":"T447","span":{"begin":613,"end":632},"obj":"Sentence"},{"id":"T448","span":{"begin":633,"end":638},"obj":"Sentence"},{"id":"T449","span":{"begin":639,"end":700},"obj":"Sentence"},{"id":"T450","span":{"begin":701,"end":739},"obj":"Sentence"},{"id":"T451","span":{"begin":740,"end":764},"obj":"Sentence"},{"id":"T452","span":{"begin":765,"end":830},"obj":"Sentence"},{"id":"T453","span":{"begin":831,"end":914},"obj":"Sentence"},{"id":"T454","span":{"begin":915,"end":984},"obj":"Sentence"},{"id":"T455","span":{"begin":985,"end":1076},"obj":"Sentence"},{"id":"T456","span":{"begin":1077,"end":1080},"obj":"Sentence"},{"id":"T457","span":{"begin":1081,"end":1285},"obj":"Sentence"},{"id":"T458","span":{"begin":1286,"end":1407},"obj":"Sentence"},{"id":"T459","span":{"begin":1408,"end":1455},"obj":"Sentence"},{"id":"T460","span":{"begin":1456,"end":1526},"obj":"Sentence"},{"id":"T461","span":{"begin":1527,"end":1678},"obj":"Sentence"},{"id":"T462","span":{"begin":1679,"end":1725},"obj":"Sentence"},{"id":"T463","span":{"begin":1726,"end":1795},"obj":"Sentence"},{"id":"T464","span":{"begin":1796,"end":1825},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"COVID-19\nStudy Wang et al (2020)N = 138, confirmed casesClinicopathologic study Guan et al (2020)N = 1099, confirmed casesRetrospective study To et al (2020)N = 12, suspected casesClinicopathologic study Xie et al (2020)N = 19 suspected (9 confirmed cases)Clinicopathologic study Pan et al (2020)N = 204, confirmed casesRetrospective study Wu et al (2020)N = 74, confirmed casesClinicopathologic study\nClinical features • Anorexia (39.9)\n• Diarrhea (10.1)\n• Nausea (10.1%)\n• Vomiting (3.6%)\n• Abdominal pain (2.2%) • Diarrhea (3.8%)\n• Nausea or vomiting (5%) Diarrhea (11.1% of confirmed) • Any GI symptom: 50.5%\n• Only GI symptoms: 0.03%\n• Loss of appetite (39.7% of total, 78.6% of all GI symptoms)\n• Diarrhea (17.1%, 34%, usually 3/day)\n• Vomiting (0.02%, 3.9%)\n• Abdominal pain (0.01%, 1.9%) Diarrhea/Vomit/Stomachache (44.6%)\nKey findings on investigations N/A N/A • 2019-nCoV detected in 91.7% saliva samples\n• Virus cultured from 3/12 saliva samples RNA positive stool samples: 88.9% of confirmed (overall 42%) ↑ALT, AST↑ PT↓monocyte count • RNA positive stool samples: 55%\nKey study findings and message ICU patients more likely to have anorexia and abdominal pain (P \u003c 0.001, P = 0.02) GI symptoms less common • Presence of GI symptoms not associated with stool RNA positivity\n• Fecal transmission possible • Patients with GI symptoms had longer interval from symptom onset to admission (P = 0.013)\n• GI symptoms worsened with severity of disease\n• Patients with GI symptoms more likely to get antibiotics (P = 0.018)\n• No association presence of GI symptoms with total hospital stay, ICU days or mortality • Presence of GI symptoms not associated with stool positivity\n• Prolonged fecal viral shedding up to 5 weeks\n• Disease severity not associated with prolonged fecal viral shedding\n• Fecal transmission possible"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T1140","span":{"begin":19,"end":23},"obj":"CHEBI:16199;CHEBI:16199"},{"id":"T1141","span":{"begin":108,"end":112},"obj":"CHEBI:16199;CHEBI:16199"},{"id":"T1142","span":{"begin":233,"end":237},"obj":"CHEBI:16199;CHEBI:16199"},{"id":"T1143","span":{"begin":403,"end":408},"obj":"GO:0016265"},{"id":"T1144","span":{"begin":531,"end":536},"obj":"GO:0016265"},{"id":"T1145","span":{"begin":585,"end":589},"obj":"CHEBI:16199;CHEBI:16199"},{"id":"T1146","span":{"begin":649,"end":654},"obj":"UBERON:0002113"},{"id":"T1147","span":{"begin":685,"end":690},"obj":"NCBITaxon:10239"},{"id":"T1148","span":{"begin":699,"end":704},"obj":"UBERON:0002405"},{"id":"T1149","span":{"begin":715,"end":720},"obj":"NCBITaxon:10239"},{"id":"T1150","span":{"begin":788,"end":793},"obj":"GO:0016265"},{"id":"T1151","span":{"begin":860,"end":864},"obj":"G_3;PG_10;PR:000003622"},{"id":"T1152","span":{"begin":866,"end":897},"obj":"PG_10;PR:000003622"},{"id":"T1153","span":{"begin":910,"end":916},"obj":"UBERON:0002113"},{"id":"T1154","span":{"begin":936,"end":941},"obj":"UBERON:0002113"},{"id":"T1155","span":{"begin":956,"end":961},"obj":"UBERON:0000178"},{"id":"T1156","span":{"begin":962,"end":966},"obj":"CHEBI:16199;CHEBI:16199"},{"id":"T1157","span":{"begin":990,"end":996},"obj":"UBERON:0002113"},{"id":"T1158","span":{"begin":1039,"end":1049},"obj":"CHEBI:16737;CHEBI:16737"},{"id":"T1159","span":{"begin":1100,"end":1107},"obj":"CHEBI:24996;CHEBI:24996"},{"id":"T1160","span":{"begin":1123,"end":1131},"obj":"SP_9"},{"id":"T1161","span":{"begin":1133,"end":1177},"obj":"SP_9"},{"id":"T1162","span":{"begin":1179,"end":1187},"obj":"SP_10"},{"id":"T1163","span":{"begin":1189,"end":1201},"obj":"SP_10"},{"id":"T1164","span":{"begin":1202,"end":1212},"obj":"SP_10;UBERON:0001004"},{"id":"T1165","span":{"begin":1213,"end":1233},"obj":"SP_10"},{"id":"T1166","span":{"begin":1260,"end":1266},"obj":"UBERON:0000970"},{"id":"T1167","span":{"begin":1329,"end":1337},"obj":"SP_10"},{"id":"T1168","span":{"begin":1376,"end":1381},"obj":"UBERON:0001827"},{"id":"T1169","span":{"begin":1454,"end":1462},"obj":"SP_10"},{"id":"T1170","span":{"begin":1520,"end":1528},"obj":"SP_10"},{"id":"T1171","span":{"begin":1550,"end":1555},"obj":"UBERON:0001827"},{"id":"T1172","span":{"begin":1569,"end":1577},"obj":"SP_9"},{"id":"T1173","span":{"begin":1578,"end":1587},"obj":"SP_9"},{"id":"T1174","span":{"begin":1612,"end":1635},"obj":"UBERON:0000010"},{"id":"T1175","span":{"begin":1651,"end":1663},"obj":"UBERON:0001016"}],"text":"COVID-19\nStudy Wang et al (2020)N = 138, confirmed casesClinicopathologic study Guan et al (2020)N = 1099, confirmed casesRetrospective study To et al (2020)N = 12, suspected casesClinicopathologic study Xie et al (2020)N = 19 suspected (9 confirmed cases)Clinicopathologic study Pan et al (2020)N = 204, confirmed casesRetrospective study Wu et al (2020)N = 74, confirmed casesClinicopathologic study\nClinical features • Anorexia (39.9)\n• Diarrhea (10.1)\n• Nausea (10.1%)\n• Vomiting (3.6%)\n• Abdominal pain (2.2%) • Diarrhea (3.8%)\n• Nausea or vomiting (5%) Diarrhea (11.1% of confirmed) • Any GI symptom: 50.5%\n• Only GI symptoms: 0.03%\n• Loss of appetite (39.7% of total, 78.6% of all GI symptoms)\n• Diarrhea (17.1%, 34%, usually 3/day)\n• Vomiting (0.02%, 3.9%)\n• Abdominal pain (0.01%, 1.9%) Diarrhea/Vomit/Stomachache (44.6%)\nKey findings on investigations N/A N/A • 2019-nCoV detected in 91.7% saliva samples\n• Virus cultured from 3/12 saliva samples RNA positive stool samples: 88.9% of confirmed (overall 42%) ↑ALT, AST↑ PT↓monocyte count • RNA positive stool samples: 55%\nKey study findings and message ICU patients more likely to have anorexia and abdominal pain (P \u003c 0.001, P = 0.02) GI symptoms less common • Presence of GI symptoms not associated with stool RNA positivity\n• Fecal transmission possible • Patients with GI symptoms had longer interval from symptom onset to admission (P = 0.013)\n• GI symptoms worsened with severity of disease\n• Patients with GI symptoms more likely to get antibiotics (P = 0.018)\n• No association presence of GI symptoms with total hospital stay, ICU days or mortality • Presence of GI symptoms not associated with stool positivity\n• Prolonged fecal viral shedding up to 5 weeks\n• Disease severity not associated with prolonged fecal viral shedding\n• Fecal transmission possible"}

{"project":"LitCovid-PubTator","denotations":[{"id":"959","span":{"begin":1024,"end":1027},"obj":"Gene"},{"id":"960","span":{"begin":1233,"end":1235},"obj":"Gene"},{"id":"961","span":{"begin":1630,"end":1632},"obj":"Gene"},{"id":"962","span":{"begin":1556,"end":1558},"obj":"Gene"},{"id":"963","span":{"begin":1472,"end":1474},"obj":"Gene"},{"id":"964","span":{"begin":1410,"end":1412},"obj":"Gene"},{"id":"965","span":{"begin":1332,"end":1334},"obj":"Gene"},{"id":"966","span":{"begin":1195,"end":1197},"obj":"Gene"},{"id":"967","span":{"begin":688,"end":690},"obj":"Gene"},{"id":"968","span":{"begin":620,"end":622},"obj":"Gene"},{"id":"969","span":{"begin":595,"end":597},"obj":"Gene"},{"id":"970","span":{"begin":872,"end":881},"obj":"Species"},{"id":"971","span":{"begin":1116,"end":1124},"obj":"Species"},{"id":"972","span":{"begin":1318,"end":1326},"obj":"Species"},{"id":"973","span":{"begin":0,"end":8},"obj":"Disease"},{"id":"974","span":{"begin":422,"end":464},"obj":"Disease"},{"id":"975","span":{"begin":475,"end":483},"obj":"Disease"},{"id":"976","span":{"begin":493,"end":507},"obj":"Disease"},{"id":"977","span":{"begin":517,"end":525},"obj":"Disease"},{"id":"978","span":{"begin":535,"end":541},"obj":"Disease"},{"id":"979","span":{"begin":545,"end":553},"obj":"Disease"},{"id":"980","span":{"begin":559,"end":567},"obj":"Disease"},{"id":"981","span":{"begin":641,"end":657},"obj":"Disease"},{"id":"982","span":{"begin":703,"end":711},"obj":"Disease"},{"id":"983","span":{"begin":742,"end":750},"obj":"Disease"},{"id":"984","span":{"begin":767,"end":781},"obj":"Disease"},{"id":"985","span":{"begin":796,"end":804},"obj":"Disease"},{"id":"986","span":{"begin":805,"end":822},"obj":"Disease"},{"id":"987","span":{"begin":1145,"end":1153},"obj":"Disease"},{"id":"988","span":{"begin":1158,"end":1172},"obj":"Disease"},{"id":"989","span":{"begin":1606,"end":1615},"obj":"Disease"}],"attributes":[{"id":"A959","pred":"tao:has_database_id","subj":"959","obj":"Gene:26503"},{"id":"A960","pred":"tao:has_database_id","subj":"960","obj":"Gene:2770"},{"id":"A961","pred":"tao:has_database_id","subj":"961","obj":"Gene:2770"},{"id":"A962","pred":"tao:has_database_id","subj":"962","obj":"Gene:2770"},{"id":"A963","pred":"tao:has_database_id","subj":"963","obj":"Gene:2770"},{"id":"A964","pred":"tao:has_database_id","subj":"964","obj":"Gene:2770"},{"id":"A965","pred":"tao:has_database_id","subj":"965","obj":"Gene:2770"},{"id":"A966","pred":"tao:has_database_id","subj":"966","obj":"Gene:2770"},{"id":"A967","pred":"tao:has_database_id","subj":"967","obj":"Gene:2770"},{"id":"A968","pred":"tao:has_database_id","subj":"968","obj":"Gene:2770"},{"id":"A969","pred":"tao:has_database_id","subj":"969","obj":"Gene:2770"},{"id":"A970","pred":"tao:has_database_id","subj":"970","obj":"Tax:2697049"},{"id":"A971","pred":"tao:has_database_id","subj":"971","obj":"Tax:9606"},{"id":"A972","pred":"tao:has_database_id","subj":"972","obj":"Tax:9606"},{"id":"A973","pred":"tao:has_database_id","subj":"973","obj":"MESH:C000657245"},{"id":"A974","pred":"tao:has_database_id","subj":"974","obj":"MESH:D009325"},{"id":"A975","pred":"tao:has_database_id","subj":"975","obj":"MESH:D014839"},{"id":"A976","pred":"tao:has_database_id","subj":"976","obj":"MESH:D015746"},{"id":"A977","pred":"tao:has_database_id","subj":"977","obj":"MESH:D003967"},{"id":"A978","pred":"tao:has_database_id","subj":"978","obj":"MESH:D009325"},{"id":"A979","pred":"tao:has_database_id","subj":"979","obj":"MESH:D014839"},{"id":"A980","pred":"tao:has_database_id","subj":"980","obj":"MESH:D003967"},{"id":"A981","pred":"tao:has_database_id","subj":"981","obj":"MESH:D001068"},{"id":"A982","pred":"tao:has_database_id","subj":"982","obj":"MESH:D003967"},{"id":"A983","pred":"tao:has_database_id","subj":"983","obj":"MESH:D014839"},{"id":"A984","pred":"tao:has_database_id","subj":"984","obj":"MESH:D015746"},{"id":"A985","pred":"tao:has_database_id","subj":"985","obj":"MESH:D003967"},{"id":"A986","pred":"tao:has_database_id","subj":"986","obj":"MESH:D014839"},{"id":"A987","pred":"tao:has_database_id","subj":"987","obj":"MESH:D000855"},{"id":"A988","pred":"tao:has_database_id","subj":"988","obj":"MESH:D015746"},{"id":"A989","pred":"tao:has_database_id","subj":"989","obj":"MESH:D003643"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"COVID-19\nStudy Wang et al (2020)N = 138, confirmed casesClinicopathologic study Guan et al (2020)N = 1099, confirmed casesRetrospective study To et al (2020)N = 12, suspected casesClinicopathologic study Xie et al (2020)N = 19 suspected (9 confirmed cases)Clinicopathologic study Pan et al (2020)N = 204, confirmed casesRetrospective study Wu et al (2020)N = 74, confirmed casesClinicopathologic study\nClinical features • Anorexia (39.9)\n• Diarrhea (10.1)\n• Nausea (10.1%)\n• Vomiting (3.6%)\n• Abdominal pain (2.2%) • Diarrhea (3.8%)\n• Nausea or vomiting (5%) Diarrhea (11.1% of confirmed) • Any GI symptom: 50.5%\n• Only GI symptoms: 0.03%\n• Loss of appetite (39.7% of total, 78.6% of all GI symptoms)\n• Diarrhea (17.1%, 34%, usually 3/day)\n• Vomiting (0.02%, 3.9%)\n• Abdominal pain (0.01%, 1.9%) Diarrhea/Vomit/Stomachache (44.6%)\nKey findings on investigations N/A N/A • 2019-nCoV detected in 91.7% saliva samples\n• Virus cultured from 3/12 saliva samples RNA positive stool samples: 88.9% of confirmed (overall 42%) ↑ALT, AST↑ PT↓monocyte count • RNA positive stool samples: 55%\nKey study findings and message ICU patients more likely to have anorexia and abdominal pain (P \u003c 0.001, P = 0.02) GI symptoms less common • Presence of GI symptoms not associated with stool RNA positivity\n• Fecal transmission possible • Patients with GI symptoms had longer interval from symptom onset to admission (P = 0.013)\n• GI symptoms worsened with severity of disease\n• Patients with GI symptoms more likely to get antibiotics (P = 0.018)\n• No association presence of GI symptoms with total hospital stay, ICU days or mortality • Presence of GI symptoms not associated with stool positivity\n• Prolonged fecal viral shedding up to 5 weeks\n• Disease severity not associated with prolonged fecal viral shedding\n• Fecal transmission possible"}